These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 28919378)

  • 1. Sudden death mechanisms in nonischemic cardiomyopathies: Insights gleaned from clinical implantable cardioverter-defibrillator trials.
    Steinberg BA; Mulpuru SK; Fang JC; Gersh BJ
    Heart Rhythm; 2017 Dec; 14(12):1839-1848. PubMed ID: 28919378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implantable cardioverter defibrillators for primary prevention in patients with nonischemic cardiomyopathy: A systematic review and meta-analysis.
    Akel T; Lafferty J
    Cardiovasc Ther; 2017 Jun; 35(3):. PubMed ID: 28129469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sudden cardiac death in nonischemic cardiomyopathy: Refining risk assessment.
    Zipse MM; Tzou WS
    J Cardiovasc Electrophysiol; 2017 Nov; 28(11):1361-1366. PubMed ID: 28670752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are implantable cardioverter defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardiomyopathy?
    Ellenbogen KA; Levine JH; Berger RD; Daubert JP; Winters SL; Greenstein E; Shalaby A; Schaechter A; Subacius H; Kadish A;
    Circulation; 2006 Feb; 113(6):776-82. PubMed ID: 16461817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylactic use of the implantable cardioverter-defibrillator and its effect on the long-term survival, cardiovascular and sudden cardiac death in nonischemic cardiomyopathy patients-a systematic review and meta-analysis.
    Siddiqui WJ; Aggarwal S; Rafique M; Singh S; Kutalek S; Eisen HJ
    Heart Fail Rev; 2018 Mar; 23(2):181-190. PubMed ID: 29380177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sudden cardiac death in nonischemic cardiomyopathy.
    Kadakia RS; Link MS; Dominic P; Morin DP
    Prog Cardiovasc Dis; 2019; 62(3):235-241. PubMed ID: 31075279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of Arrhythmic Death in Patients With Nonischemic Cardiomyopathy: JACC Review Topic of the Week.
    Chrispin J; Merchant FM; Lakdawala NK; Wu KC; Tomaselli GF; Navara R; Torbey E; Ambardekar AV; Kabra R; Arbustini E; Narula J; Guglin M; Albert CM; Chugh SS; Trayanova N; Cheung JW
    J Am Coll Cardiol; 2023 Aug; 82(8):735-747. PubMed ID: 37587585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale and study protocol for the BRITISH randomized trial (Using cardiovascular magnetic resonance identified scar as the benchmark risk indication tool for implantable cardioverter defibrillators in patients with nonischemic cardiomyopathy and severe systolic heart failure).
    Flett A; Cebula A; Nicholas Z; Adam R; Ewings S; Prasad S; Cleland JG; Eminton Z; Curzen N
    Am Heart J; 2023 Dec; 266():149-158. PubMed ID: 37777041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implantable cardioverter defibrillators for primary prevention in patients with ischemic and non-ischemic cardiomyopathy: A meta-analysis.
    Jaiswal V; Taha AM; Joshi A; Deb N; Kanagala SG; Nebuwa C; Ang SP; Halder A; Rajak K; Jha M; Pallath Harshakumar S; Mattumpuram J
    Curr Probl Cardiol; 2024 Feb; 49(2):102198. PubMed ID: 37952790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary Prevention Implantable Cardioverter Defibrillators in Patients With Nonischemic Cardiomyopathy: A Meta-analysis.
    Al-Khatib SM; Fonarow GC; Joglar JA; Inoue LYT; Mark DB; Lee KL; Kadish A; Bardy G; Sanders GD
    JAMA Cardiol; 2017 Jun; 2(6):685-688. PubMed ID: 28355432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current Indications for Implantable Cardioverter Defibrillators in Non-Ischemic Cardiomyopathies and Channelopathies.
    González-Torrecilla E; Arenal A; Atienza F; Datino T; Bravo L; Ruiz P; Ávila P; Fernández-Avilés F
    Rev Recent Clin Trials; 2015; 10(2):111-27. PubMed ID: 25845953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Implantable Cardioverter-Defibrillator Therapy in Patients With Nonischemic Cardiomyopathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Anantha Narayanan M; Vakil K; Reddy YN; Baskaran J; Deshmukh A; Benditt DG; Adabag S
    JACC Clin Electrophysiol; 2017 Sep; 3(9):962-970. PubMed ID: 29759721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mortality Effect of ICD in Primary Prevention of Nonischemic Cardiomyopathy: A Meta-Analysis of Randomized Controlled Trials.
    Luni FK; Singh H; Khan AR; Malik SA; Khawaja O; Riaz H; Lee W; Kabour A; Richards M; Aasbo J
    J Cardiovasc Electrophysiol; 2017 May; 28(5):538-543. PubMed ID: 28370885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis.
    Varr BC; Zarafshar S; Coakley T; Liedtke M; Lafayette RA; Arai S; Schrier SL; Witteles RM
    Heart Rhythm; 2014 Jan; 11(1):158-62. PubMed ID: 24121001
    [No Abstract]   [Full Text] [Related]  

  • 15. Primary prevention implantable cardioverter-defibrillator and opportunities for sudden cardiac death risk assessment in non-ischaemic cardiomyopathy.
    Pathak RK; Sanders P; Deo R
    Eur Heart J; 2018 Aug; 39(31):2859-2866. PubMed ID: 30020440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials.
    Desai AS; Fang JC; Maisel WH; Baughman KL
    JAMA; 2004 Dec; 292(23):2874-9. PubMed ID: 15598919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of implantable cardioverter defibrillator in non-ischemic cardiomyopathy: a systematic review and meta-analysis of prospective randomized clinical trials.
    Romero J; Chaudhary R; Garg J; Lupercio F; Shah N; Gupta R; Nazir T; Bozorgnia B; Natale A; Di Biase L
    J Interv Card Electrophysiol; 2017 Sep; 49(3):263-270. PubMed ID: 28674918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implantable Cardioverter-Defibrillators for Primary Prevention in Patients With Ischemic or Nonischemic Cardiomyopathy: A Systematic Review and Meta-analysis.
    Kolodziejczak M; Andreotti F; Kowalewski M; Buffon A; Ciccone MM; Parati G; Scicchitano P; Uminska JM; De Servi S; Bliden KP; Kubica J; Bortone A; Crea F; Gurbel P; Navarese EP
    Ann Intern Med; 2017 Jul; 167(2):103-111. PubMed ID: 28632280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival benefit of the primary prevention implantable cardioverter-defibrillator among older patients: does age matter? An analysis of pooled data from 5 clinical trials.
    Hess PL; Al-Khatib SM; Han JY; Edwards R; Bardy GH; Bigger JT; Buxton A; Cappato R; Dorian P; Hallstrom A; Kadish AH; Kudenchuk PJ; Lee KL; Mark DB; Moss AJ; Steinman R; Inoue LY; Sanders G
    Circ Cardiovasc Qual Outcomes; 2015 Mar; 8(2):179-86. PubMed ID: 25669833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sudden cardiac death while waiting: do we need the wearable cardioverter-defibrillator?
    Israel C; Staudacher I; Leclercq C; Botto GL; Scherr D; Fach A; Duru F; Zylla MM; Katus HA; Thomas D
    Clin Res Cardiol; 2022 Nov; 111(11):1189-1197. PubMed ID: 35305126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.